Skip to main content

Table 1 Basic characteristics of cervical cancer cases and cancer-free controls

From: Mitochondrial DNA copy number in cervical exfoliated cells and risk of cervical cancer among HPV-positive women

Variables

Cases (n = 591)

Controls (n = 373)

P

N (%)

N (%)

Age, years

  

0.36 e

 < 50

339(57.36)

226(60.59)

 

 ≥ 50

252(42.64)

147(39.41)

 

HPV16

  

< 0.001e

 Negative

268(45.35)

300(80.43)

 

 Positive

323(54.65)

73(19.57)

 

HPV18

  

0.43 e

 Negative

532(90.02)

342(91.69)

 

 Positive

59(9.98)

31(8.31)

 

HPV52

  

< 0.001e

 Negative

488(82.57)

272(72.92)

 

 Positive

103(17.43)

101(27.08)

 

HPV58

  

0.005e

 Negative

536(90.69)

315(84.45)

 

 Positive

55(9.31)

58(15.55)

 

Other type a

  

< 0.001e

 Negative

481(81.39)

239(64.08)

 

 Positive

110(18.61)

134(35.92)

 

Multiple infection

  

0.15e

 Negative

538(91.03)

350(93.83)

 

 Positive

53(8.97)

23(6.17)

 

Grade b

 High

27(7.99)

  

 Middle

178(52.66)

  

 Low

133(39.35)

  

Histology c

 Squamous

536(94.87)

  

 Adeno/adenosquamous

29(5.13)

  

FIGO d

 I/II

366(83.75)

  

 III/IV

71(16.25)

  

 mtCN (median, quartile)

1.63(0.59–3.43)

1.23(0.53–2.76)

0.03f

  1. Bold values indicate P < 0.05
  2. Abbreviation: HPV human papillomavirus, FIGO International Federation of Gynecology and Obstetrics, mtCN mitochondrial DNA copy number
  3. aOthers include HPV31, 33, 35, 39, 45, 51, 56, 59, 66, and 68
  4. bGrade information was available in 338 cervical cancer cases
  5. cHistological information was available in 565 cases
  6. dFIGO information was available in 437 cervical cancer cases
  7. eDerived from χ2 test
  8. fDerived from Wilcoxon rank-sum test